Form 4: Nurix Therapeutics CFO Hans van Houte Reports Stock Transactions

Hans van Houte, CFO of Nurix Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.

Summary

• On April 30, 2025, Hans van Houte, the CFO of Nurix Therapeutics, reported transactions involving the company's common stock and restricted stock units (RSUs).
• He acquired shares through the vesting of RSUs and simultaneously sold a portion of those shares to cover tax withholding obligations.
• Specifically, 2,886, 2,000 and 3,750 shares were acquired through RSU vesting.
• 2,438 shares were sold at a weighted average price of $11.5017 to cover tax obligations.
• Following these transactions, van Houte directly owns 39,922 shares of Nurix Therapeutics common stock and varying amounts of restricted stock units.

Sentiment

Score: 5

Explanation: This is a routine filing related to executive compensation and tax obligations. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Positives

• The vesting of RSUs indicates that the CFO is meeting the service requirements of his equity grants.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to provide transparency into the transactions of company insiders. They are closely watched by investors seeking to understand management's perspective on the company's stock.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units (RSUs) that vest over time, aligning management's interests with those of shareholders.
• The 'sell to cover' practice for tax obligations is a common mechanism used by companies to manage the tax implications of equity compensation for their employees.
• The vesting schedules described (quarterly over three or four years) are typical vesting arrangements for RSUs in the biotechnology industry.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they primarily relate to the CFO's personal financial management of equity compensation.

Key Dates

Keywords

Nurix Therapeutics, NRIX, Hans van Houte, CFO, Form 4, Stock Transactions, Restricted Stock Units, RSU, Beneficial Ownership, Tax Withholding